Phase 2, Phase 3 Recruiting Academic/Other
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Sponsor: NRG Oncology
NCT ID: NCT05174169
Sites in Florida: - AdventHealth Altamonte — Altamonte Springs, Florida
- AdventHealth Celebration — Celebration, Florida
- Morton Plant Hospital — Clearwater, Florida
- Holy Cross Hospital — Fort Lauderdale, Florida
- UF Health Cancer Institute - Gainesville — Gainesville, Florida
Phase 3 Recruiting Network
This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Sites in Florida: - Schulze Family Foundation Cancer Clinic - Bonita Health Center — Bonita Springs, Florida
- Holy Cross Hospital — Fort Lauderdale, Florida
- Regional Cancer Center-Lee Memorial Health System — Fort Myers, Florida
Phase 3 Recruiting Industry
The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy …
Sponsor: Pfizer
NCT ID: NCT07222800
Sites in Florida: - Florida Cancer Specialists — Bonita Springs, Florida
- Florida Cancer Specialists — Bradenton, Florida
- Comprehensive Hematology Oncology — Brandon, Florida
- Florida Cancer Specialists — Cape Coral, Florida
- BRCR Global - Coral Springs — Coral Springs, Florida
Phase 3 Recruiting Industry
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participa…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT05253651
Sites in Florida: - Mount Sinai Medical Center Aventura ER — Aventura, Florida
- Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida
- Mount Sinai Medical Center — Miami Beach, Florida
Phase 3 Recruiting Industry
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Tr…
Sponsor: Summit Therapeutics
NCT ID: NCT07228832
Sites in Florida: - Clinical Study Site — Hialeah, Florida
- Clinical Study Site — Miami, Florida
- Clinical Study Site — Miami Beach, Florida
- Clinical Study Site — Ocala, Florida
- Clinical Study Site — Orlando, Florida
Phase 3 Recruiting Network
This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limit…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06205485
Sites in Florida: - Orlando Health Cancer Institute — Orlando, Florida
Phase 3 Recruiting Industry
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fl…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06750094
Sites in Florida: - Florida Cancer Specialists South — Fort Myers, Florida
- Mount Sinai Medical Center Campus — Miami Beach, Florida
- AdventHealth Cancer Institute — Orlando, Florida
- Florida Cancer Specialists North Region — St. Petersburg, Florida
- Florida Cancer Specialists East — West Palm Beach, Florida
Phase 3 Recruiting Network
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the li…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT05863195
Sites in Florida: - UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
- UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
- UM Sylvester Comprehensive Cancer Center at Hollywood — Hollywood, Florida
- University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic color…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07221357
Sites in Florida: - Florida Cancer Specialists - East — Cape Coral, Florida
- Florida Cancer Specialists - North — St. Petersburg, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 3 Recruiting Industry
The main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in patients diagnosed with Familial Adenomatous Polyposis (FAP). Researchers will compare eRapa to Placebo. The questions to b…
Sponsor: Rapamycin Holdings Inc.
NCT ID: NCT06950385
Sites in Florida: - Digestive & Liver Center of Florida — Orlando, Florida
- Cleveland Clinic Florida — Weston, Florida
Phase 3 Recruiting Industry
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard…
Sponsor: AbbVie
NCT ID: NCT07525206
Sites in Florida: - Moffitt Cancer Center /ID# 279325 — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Florida: - Memorial Healthcare System — Hollywood, Florida
- Local Institution - 2113 — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Florida: - Florida Cancer Specialists — Fort Myers, Florida
- Mayo Clinic (Florida) — Jacksonville, Florida
- Cancer Specialists of North Florida — Jacksonville, Florida
- Florida Cancer Specialists — Orlando, Florida
- Florida Cancer Specialists — Sarasota, Florida
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in Florida: - Mayo Clinic Cancer Center — Jacksonville, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Florida: - University of Miami - Sylvester Comprehensive Cancer Center — Miami, Florida
- Advent Health — Orlando, Florida
- Florida Cancer Specialists South — Port Charlotte, Florida
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in Florida: - Mayo Clinic — Jacksonville, Florida
- Florida Cancer Specialists — Lake Mary, Florida
Phase 1, Phase 2 Recruiting Industry
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment wa…
Sponsor: Boehringer Ingelheim
NCT ID: NCT06324357
Sites in Florida: - Helios CR Inc — Lakeland, Florida
- H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
Phase 2 Recruiting Industry
This is a randomized, double-blind, placebo-controlled basket trial evaluating mifomelatide (TCMCB07) administered daily by subcutaneous (SC) injection in up to 120 patients. Patients will be enrolled into two cohorts 1) patients with newl…
Sponsor: Endevica Bio
NCT ID: NCT06937177
Sites in Florida: - Life Clinical Trials — Coral Springs, Florida
- Bioresearch Partners — Hialeah, Florida
- D&H Cancer Research Center — Margate, Florida
- Mt. Sinai Cancer Center — Miami Beach, Florida
- BRCR Global — Tamarac, Florida
Phase 2 Recruiting Industry
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer
Sponsor: Verastem, Inc.
NCT ID: NCT07659795
Sites in Florida: - BRCR - Coral Springs — Coral Springs, Florida
- BRCR - Tamarac — Tamarac, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 2 Recruiting Industry
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given al…
Sponsor: AbbVie
NCT ID: NCT07023289
Sites in Florida: - Mayo Clinic Hospital Jacksonville /ID# 274472 — Jacksonville, Florida
- Moffitt Cancer Center /ID# 274372 — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT05379985
Sites in Florida: - Moffitt Cancer Center — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07488676
Sites in Florida: - Miami Cancer Institute — Miami, Florida
Phase 1, Phase 2 Recruiting Industry
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the bo…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06428409
Sites in Florida: - University of Florida College of Medicine ( Site 0281) — Gainesville, Florida
- Mount Sinai Cancer Center ( Site 0287) — Miami Beach, Florida
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of…
Sponsor: Tasca Therapeutics
NCT ID: NCT07030257
Sites in Florida: - Florida Cancer Specialists-Lake Nona — Orlando, Florida
Phase 2 Recruiting Industry
A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.
Sponsor: NGM Biopharmaceuticals, Inc
NCT ID: NCT07033026
Sites in Florida: - NGM Clinical Study Site — Margate, Florida